Legend Biotech Corp (LEGN) Operating Leases (2019 - 2024)
Legend Biotech (LEGN) has disclosed Operating Leases for 6 consecutive years, with $44.6 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Operating Leases rose 1.01% year-over-year to $44.6 million, compared with a TTM value of $44.6 million through Dec 2024, up 1.01%, and an annual FY2024 reading of $44.6 million, up 1.01% over the prior year.
- Operating Leases was $44.6 million for Q4 2024 at Legend Biotech, up from $44.2 million in the prior quarter.
- Across five years, Operating Leases topped out at $44.6 million in Q4 2024 and bottomed at $1.9 million in Q4 2020.
- Average Operating Leases over 5 years is $23.4 million, with a median of $23.6 million recorded in 2022.
- The sharpest move saw Operating Leases crashed 62.26% in 2020, then soared 842.57% in 2022.
- Year by year, Operating Leases stood at $1.9 million in 2020, then surged by 31.17% to $2.5 million in 2021, then skyrocketed by 842.57% to $23.6 million in 2022, then surged by 87.14% to $44.2 million in 2023, then rose by 1.01% to $44.6 million in 2024.
- Business Quant data shows Operating Leases for LEGN at $44.6 million in Q4 2024, $44.2 million in Q4 2023, and $23.6 million in Q4 2022.